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Editorial
Is Implantable Cardioverter Defibrillator Useful in Non-Ischaemic
Cardiomyopathy Useful?
CHU-PAK LAU,1 HUNG-FAT TSE,1-3* CHUNG-WAH SIU1,2*
From 1Cardiology Division, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong
Kong; 2Division of Cardiology, Department of Medicine, The University of Hong Kong Shenzhen Hospital, China;
3
Shenzhen Institutes of Research and Innovation, University of Hong Kong, China

Dilated cardiomyopathy (DCM) is defined as left
ventricular dilation and enlargement not due to loading
condition of the heart which cannot be explained by
epicardial coronary artery disease.1 It has a prevalence
of 1/2,500 population, and an annual incidence of
7/100,000. DCM affects men more than women. The
causes of cardiovascular death are due to arrhythmias
or progressive heart failure. Sudden cardiac death (SCD)
is more often due to ventricular tachyarrhythmias (VA),
whereas bradycardia and pulseless electrical activities
predominate as heart failure progress.2
Familial type of DCM can be due to mutations in
sarcomere and desmosomal protein gene, proteins that
directly affect cardiac contractile muscle. An important
gene is the lamin A/C mutations, in which patients
present with asymptomatic conduction disease for
decades, followed by atrial arrhythmias and VA and
DCM. In the setting of a familial occurrence of DCM
and conduction disturbance, screening of lamin A/C
mutation and SCN5A genes are recommended.
A mutation specific screening is indicated in family
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members if a patient has documented mutation in a DCM
related genes.3
The majority of DCM patients do not have a
familial incidence. Hence predictors of future VA have
relied on risk factors testing. These include (1)
autonomic parameters, (2) structural/functional
parameters such as left ventricular ejection fraction
(LVEF) and ventricular dismission; and (3) arrhythmia
indicators such as electrophysiology testing, and
electrocardiographic (ECG) depolarisation and
repolarisation abnormalities. In a meta-analysis of 12
conventional parameters involving 45 trials in 6,088
patients, 4 autonomic parameters were found to be
unpredictive. Structural/functional and ECG parameters
are helpful, but their overall specificity ranges only from
36.2 to 87.3%, with a sensitivity of 28.8-91.0%. Indeed,
LVEF, the basis on which implantable cardioverter
defibrillators (ICD) therapy is prescribed, has only a
sensitivity and specificity of 71.7 and 50.5% and a
positive predictive accuracy of 21.9%.
VA originated from trigger or reentry, often from
fibrous tissues that develop in the myocardium of DCM.
The use of late gadolinium enhancement (LGE) to detect
LV scarring has been proposed as a marker of VA.
Indeed, positive LGE in the LV increase the VA risk
almost 10 folds, both in patients with LVEF below and
above 35%.5 In a recent cohort studies that include only
patients with milely impaired LVEF of ≥40%, the 4 year
arrhythmic risk was 17.8% vs 2.3% in those with and
without LGE.6 LGE defines the VA substrate and many
emerge as a good marker to predict SCD independent
of the LVEF.
What are our therapeutics means now to combat
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SCD in patients with DCM? Obviously, optimal
pharmacological therapy of heart failure is essential.
Triggers for VA such as hypokalaemia, thyrotoxicosis
and new onset ischaemia should be promptly diagnosed
and treated. VA ablation can be performed, but due to
the often patchy fibrosis that can involve multiple
myocardial layers, the success rate of VA ablation is
less durable than VA ablation in cardiomyopathy due to
ischaemic heart disease,7 notwithstanding the low acute
success rate of 22.2%.
Implantation of ICD is the recommended therapy
in those survivors of SCD and VA in DCM. For primary
prevention, both the ACC/AHA8 and ESC1 guidelines
have used LVEF and the degree of symptomatic heart
failure as criteria for ICD prescription: In patients with
DCM and an LVEF ≤35%, with NYHA class I - IV are
for ICD implantation. These are based on the CAT,9
AMIOVIRT,10 DEFINITE11 and the SCD-HeFT12 studies
which were published before 2005. These studies
showed a combined 31% of reduction in total mortality
in the ICD therapy vs medical therapy arms, a result
mainly driven by a 56% SCD reduction.
In view of the change in medical therapy that has
occurred over the last 15 years, the advent of the cardiac
resynchronization therapy (CRT), the increase in patient
longevity, and the frequent associated co-morbidities
which increases the proportion of death for nonarrhythmic disease, the role of the ICD has now been
questioned.
The COMPANION trial13 has involved patients
with both DCM and ischemic heart failure who are in
Class III-IV heart failure with a wide QRS width, a group
that has high baseline mortality. The use of cardiac
resynchronization therapy defibrillator (CRT-D) but not
CRT reduces total mortality over medical therapy,
although it is not sure the effect is due to ICD or CRT
alone. Indeed, the study did not show mortality
difference between CRT-D vs CRT.
The recent DANISH trial14 is a focus study on
this issue. In a randomized control study of 1,116
patients with heart failure, half of them were randomized
to ICD (or CRT-D) and half to medical therapy (or
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corresponding CRT). CRT-D or CRT were used in 58%
in total. ICD/CRT-D therapy was shown not to change
the risk of total mortality vs control arm over a median
of over 5 years of follow up, although the SCD risk was
significantly reduced from 8.3 to 4.3%. The study was
powered to detect a difference of 25% total mortality.
According to the authors, this difference from prior trials
of ICD can be due to less VA risk in DCM than ischaemic
cardiomyopathy, the beneficial impact of CRT, and the
high percentage of use of angiotensin-receptor and
betablockers (>90%) compared to older studies, and
vigorous exclusion of coronary artery disease.
Figure 1 shows the demographics and the SCD
rates in the controlled arms of the major studies of ICD
in DCM. With the exception of the COMPANION trial,
which is a CRT trial in sicker patients, the DANISH
recruited the oldest patients, had the longest follow up
and the lowest annual mortality. In addition, there was
an initial separation of mortality rates between the ICD
vs control arms, although the 2 curves come together
with follow up, quite unlike the continued separation of
ICD trial for MADIT-II15 for ischaemic cardiomyopathy
(Figure 2). This suggests that over time with progression
of heart failure or development of comorbidities or both
in these patients, the benefit of ICD in DCM is reduced.
Several meta-analysis have since been published
combining these trial data. The total mortality reduction
for all trials using ICD/CRT-D and ICD only were 24
and 23% reduction, whereas CRT-D did not reduce
mortality. 16 Such meta-analyse that include trials
performed at disparate time are limited by major
difference in the patients demographic and changes in
heart failure treatment.
In conclusion, the benefit (if present) of primary
prevention for mortality in DCM is now significantly
reduced due to better medical care and the use of CRT.
Nevertheless, the benefit on SCD prevention remains
valid. Better identification of subjects with higher risk
of SCD such as younger patients and those with
LGE may allow a better cost-performance of ICD,
although dedicated trials using these parameters will be
needed.
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Figure 1. Demographic and outcome of 6 randomized trials on implantable cardioverter defibrillator in nonischaemic dilated cardiomyopathy.9-14

Figure 2. Total mortality between implantable cardioverter defibrillator and control arm in dilated cardiomyopathy
(DANISH trial14) and ischaemic cardiomyopathy (MADIT-II long term outcome15). The curves separate and converge
overtime for dilated cardiomyopathy, but continue to separate in the ischaemic cardiomyopathy trial.
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